Hani Gabra is Professor of Medical Oncology and Deputy Head of the Division of Cancer (Clinical).
He is Head of the Molecular Therapeutics Unit and Director of the Ovarian Cancer Action Research Centre at Imperial College.
Within Imperial College Healthcare NHS Trust he is Head of Medical Oncology, Chair of the Cancer Research Committee and is Honorary Consultant Medical Oncologist.
He is also Associate Director and Lead of the Cancer Division (Division 1) of the NIHR Clinical Research Network for North West London.
Hani studied Medicine at the University of Glasgow and graduated with a BSc (Hons) in Molecular Biology and MB ChB in 1987. After obtaining MRCP(UK) in 1990, he undertook an MSc in Clinical Oncology and a PhD in Molecular Oncology from the University of Edinburgh. He then completed his specialist training in Cancer Medicine in Edinburgh and was CRUK Clinical Scientist and Consultant Medical Oncologist at the CRUK Edinburgh Medical Oncology Unit from 1998-2003 when he came to Imperial as Chair in Medical Oncology.
He is a Fellow of the Royal College of Physicians of Edinburgh and London.
As well as leading the Ovarian Cancer Programme at Imperial, his laboratory is involved in trying to understand the role of tumour suppressor genes in ovarian cancer, particularly how OPCML regulates networks of receptor tyrosine kinases and how WWOX acts to regulate taxane sensitivity.
His clinical / translational interests relate to the understanding of platinum resistance in ovarian cancer, and he has developed several molecular targets whose inhibition can reverse platinum resistance from laboratory to clinic; such targets include AKT, MTOR, HDAC4, STAT1 and the Folate Receptors.
He is President of the European Translational Ovarian Cancer Network (EUTROC), a multinational group that undertakes science in ovarian cancer clinical trials, principally in the context of complex phase II clinical trials.
He currently sits on the CRUK CTAAC funding committee for the UK and the INCa Scientific Evaluation Committee, Institut National Du Cancer of France.
He is on the Editorial Boards of several journals including Gynecologic Oncology and the European Journal of Cancer.
Hani's research is principally funded by Ovarian Cancer Action, the national ovarian cancer charity. He is also funded by CRUK and EU FP7 as well as translational / clinical trials funding from pharmaceutical collaborations.
et al., 2016, Response to sunitinib (Sutent) in chemotherapy refractory clear cell ovarian cancer., Gynecol Oncol Rep, Vol:18, Pages:42-44
et al., 2016, The GAS6-AXL signaling network is a mesenchymal (Mes) molecular subtype-specific therapeutic target for ovarian cancer, Science Signaling, Vol:9, ISSN:1945-0877
et al., 2016, Platinum-based chemotherapy induces methylation changes in blood DNA associated with overall survival in ovarian cancer patients., Clin Cancer Res, ISSN:1078-0432
et al., 2016, Maximal effort cytoreductive surgery for disseminated ovarian cancer in a UK setting: challenges and possibilities, Archives of Gynecology and Obstetrics, Vol:294, ISSN:0932-0067, Pages:607-614
et al., 2016, Metabonomic analysis of ovarian tumour cyst fluid by proton nuclear magnetic resonance spectroscopy, Oncotarget, Vol:7, ISSN:1949-2553, Pages:7216-7226